Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 1, 2017, Pages 160-168

  Petta, S ^a   Cabibbo, G ^a   Barbara, M ^a   Attardo, S ^a   Bucci, L ^a   Farinati, F ^a   Giannini, E G ^a   Tovoli, F ^a   Ciccarese, F ^b   Rapaccini, G L ^a   Di Marco, M ^c   Caturelli, E ^a   Zoli, M ^a   Borzio, F ^a   Sacco, R ^a   Virdone, R ^a   Marra, F ^a   Felder, M ^a   Morisco, F ^a   Benvegnu L ^a   Gasbarrini, A ^a   Svegliati Baroni, G ^a   Foschi, F G ^a   Olivani, A ^a   Masotto, A ^a   Nardone, G ^a   Colecchia, A ^a   Persico, M ^a   Boccaccio, V ^a   Craxi A ^a   Bruno, S ^a   Trevisani, F ^a   Camma C ^a   Biselli, Maurizio ^d   Caraceni, Paolo ^d   Cucchetti, Alessandro ^d   Domenicali, Marco ^d   Piscaglia, Fabio ^d   Gramenzi, Annagiulia ^d   Granito, Alessandro ^d   Magalotti, Donatella ^d   Serra, Carla ^d   Negrini, Giulia ^d   Napoli, Lucia ^d   Salvatore, Veronica ^d   Benevento, Francesca ^d   Gazzola, Alessia ^e   Murer, Francesca ^e   Pozzan, Caterina ^e   Vanin, Veronica ^e   Moscatelli, Alessandro ^f   Pellegatta, Gaia ^f   Picciotto, Antonino ^f   Savarino, Vincenzo ^f   DelPoggio, Paolo ^g   Olmi, Stefano ^g   deMatthaeis, Nicoletta ^h   Balsamo, Claudia ⁱ   Vavassori, Elena ⁱ   Roselli, Paola ^j   Dell’Isola, Serena ^k   Ialungo, Anna Maria ^k   Rastrelli, Elena ^k   Rini, Francesca ^l   Costantino, Andrea ^l   Affronti, Andrea ^l   Affronti, Marco ^l   Mascari, Marta ^l   Mega, Andrea ^m   Pompili, Maurizio ^h   Rinninella, Emanuele ^h   Mismas, Valeria ⁿ   Dall’Aglio, Anna Chiara ^o   Feletti, Valentina ^o   Lanzi, Arianna ^o   Cappa, Federica Mirici ^o   Neri, Elga ^o   Stefanini, Giuseppe Francesco ^o   Tamberi, Stefano ^o   Biasini, Elisabetta ^p   Missale, Gabriele ^p   Guarino, Maria ^q   Ortolani, Alessio ^r   Chiaramonte, Maria ^s   Marchetti, Fabiana ^s   Valerio, Matteo ^s   Aburas, Sami ^t   Inghilesi, Andrea L ^t   Cappelli, Alberta ^u   Golfieri, Rita ^u   Mosconi, Cristina ^u   Renzulli, Matteo ^u   Coccoli, Piero ^q   Zamparelli, Marco Sanduzzi ^q   more..

^a DipartimentodiScienzeMedicheeChirurgicheAlmaMaterStudiorum–UniversitàdiBologna ^*  (Italy)

^b Policlinico San Marco   (Italy)

^c UniversitàdiGenova ^*  (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g UnitàOperativadiChirurgia PoliclinicoS Marco   (Italy)

^h Dipto Gastroenterologia/Med Int   (Italy)

ⁱ Unit OperativadiMedicinaAziendaOspedalieraBolognini   (Italy)

^j OspedaleBelcolle   (Italy)

^k OspedaleBelcolle   (Italy)

^l Divisione Medicina Interna e Specialistica   (Italy)

^m Ospedale di Bolzano   (Italy)

ⁿ UNIVERSITY OF PISA   (Italy)

^o DipartimentodiMedicinaInternaOspedalepergliInfermidiFaenza   (Italy)

^p UNIVERSITY HOSPITAL OF PARMA   (Italy)

^q Dipartimento di Medicina Clinica e Chirurgia   (Italy)

^r CP68   (Italy)

^s UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^t SOD Medicina Interna   (Italy)

^u DipartimentodiMedicinaDiagnosticaePrevenzione   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; TUMOR ABLATION; VIRAL CLEARANCE; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FACTUAL DATABASE; FOLLOW UP; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84996486817     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13821     Document Type: Article

References (32)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917.
2. Alazawi W, Cunningham M, Dearden J, et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010; 32: 344–55.
3. Bucci L, Garuti F, Camelli V, et al.; Italian Liver Cancer (ITA.LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther 2016; 43: 385–99.
4. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–43.
5. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150: 835–53.
6. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liv 2015; 9: 267–317.
7. Mazzaferro V, Lencioni R, Majno P. Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. Semin Liver Dis 2014; 34: 415–26.
8. Llovet JM, Di Bisceglie AM, Bruix J, et al.; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698–711.
9. Cabibbo G, Reig M, Gadaleta-Caldarola G, et al. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 - part 2. Future Oncol 2016; 12: 285–8.
10. Bruix J, Takayama T, Mazzaferro V, et al.; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344–54.
11. Di Marco V, Calvaruso V, Ferraro D, et al. Effects of viral eradication in patients with hepatitis C virus and cirrhosis differ with stage of portal hypertension. Gastroenterology 2016; 151: 130–9.
12. Petta S, Di Marco V, Bruno S, et al. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Liver Int 2016; doi: 10.1111/liv.13156 [Epub ahead of print]
13. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17: 287–92.
14. Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 32: 851–8.
15. Miao RY, Zhao HT, Yang HY, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2010; 16: 2931–42.
16. Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS ONE 2013; 8: e61361.
17. Zhang W, Song TQ, Zhang T, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol 2014; 2: 1125–34.
18. Reig M, Mariño Z, Perelló C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 2016; 65: 719–26.
19. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727–33.
20. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646–9.
21. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864–71.
22. Garcia-Tsao G, Sanyal AJ, Grace ND, et al.; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922–38.
23. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–55.
24. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–9.
25. Suou T, Mitsuda A, Koda M, et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001; 20: 301–11.
26. Jeong SC, Aikata H, Katamura Y, et al. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007; 13: 5343–50.
27. Kanogawa N, Ogasawara S, Chiba T, et al. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol 2015; 30: 1197–204.
28. Cammà C, Cabibbo G, Craxì A. Direct antiviral agents and risk for hepatocellular carcinoma early recurrence: much ado about nothing. J Hepatol 2016; 65: 861–2.
29. Rohatgi A. WebPlotDigitizer. Available at: http://arohatgi.info/WebPlotDigitizer (accessed May 2016).
30. Giannini EG, Sammito G, Farinati F, et al.; Italian Liver Cancer (ITA.LI.CA) Group. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer 2014; 120: 2150–7.
31. Tatsumi T, Takehara T. Impact of NK cells on chronic hepatitis C and hepatocellular carcinoma. Hepatol Res 2016; 46: 416–22.
32. Brownell J, Polyak SJ. Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res 2013; 19: 1347–52.